<p>2025 年 9 月 11 日- 上午 7:42</p>
<p>佛羅里達州西棕櫚灘，2025 年 9 月 11 日（GLOBE NEWSWIRE）-- <strong>FOXO Technologies Inc.(OTC:FOXO)</strong>（“公司”）宣佈已簽署股票購買協議，以收購 Vector Biosource Inc.（“Vector”）。Vector 是一家為生物技術、臨牀研究和製藥研究行業提供信息、數據和生物樣本來源的供應商。Vector 在 2025 年第二季度的淨收入約為 225,000 美元（按年化計算為 90 萬美元），預計在收購後將顯著增長。</p>
<p>預計購買價格包括：（i）50 萬美元現金，（ii）60,000 股公司的 E 系列累積可贖回優先股（“E 系列優先股”）（面值 150 萬美元），（iii）以比收盤價高 10% 的溢價購買 200 萬美元公司普通股的認股權證，以及（iv）最多額外 80,000 股 E 系列優先股（面值最多 200 萬美元），這取決於在未來 12 到 24 個月內實現某些收入和現金回收里程碑。預計在滿足多項成交條件後儘快完成交易，包括但不限於盡職調查的完成和認股權證及僱傭協議的最終確定。此外，FOXO 已同意為 Vector 的增長計劃提供最多 120 萬美元的資金。有關 Vector Biosource 的信息可以在 www.vectorbiosource.com 找到。</p>
<p>“我們很高興與 Vector 達成協議，推進這一戰略收購，” FOXO 首席執行官 Seamus Lagan 表示。“我們被 Vector 在醫療服務領域的地位、其商業基本面和增長前景所吸引，並打算與 Vector 的高級領導層緊密合作，通過有機增長和潛在收購積極擴展 Vector。” Vector 的首席執行官 Frank Dias, Jr.解釋道：“我們相信與 FOXO 的合作將使 Vector 能夠通過提供增長資金、企業基礎設施和與其他 FOXO 子公司的潛在協同效應，實現其近期和長期的增長計劃。”</p>
<p>本新聞稿不構成出售任何證券的要約或購買任何證券的要約邀請。任何要約、購買要約的邀請或任何證券的銷售將根據《1933 年證券法》（修訂版）（“證券法”）的註冊要求進行。本公告是根據證券法第 135 條發佈的。</p>
<p><strong>關於 FOXO Technologies Inc.（“FOXO”）</strong></p>
<p>FOXO 擁有並運營三家子公司。</p>
<p>Rennova Community Health, Inc.擁有並運營 Scott County Community Hospital, Inc.（以 Big South Fork Medical Center 為名），這是位於東田納西州的一家關鍵接入醫院（CAH）。</p>
<p>Myrtle Recovery Centers, Inc.是一家位於東田納西州的 30 牀位行為健康設施。Myrtle 提供住院戒毒和住院治療服務，以及 MAT 和 OBOT 項目的門診服務。</p>
<p>FOXO Labs, Inc.是一家生物技術公司，致力於通過開發尖端技術和產品解決方案來改善人類健康和壽命，服務於各個行業。</p>
<p>有關 FOXO 的更多信息，請訪問 www.foxotechnologies.com。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含前瞻性聲明。這些聲明是在 1995 年美國私人證券訴訟改革法的 “安全港” 條款下作出的。非歷史事實的聲明，包括關於 FOXO 的信念和期望的聲明，均為前瞻性聲明。前瞻性聲明涉及固有的風險和不確定性，許多因素可能導致實際結果與任何前瞻性聲明中包含的結果有重大差異。這些因素包括但不限於 FOXO 所處的競爭激烈且高度監管的行業中變化的風險；競爭對手之間的運營表現差異或影響 FOXO 業務的法律法規變化；實施 FOXO 的商業計劃、預測和其他期望的能力；獲得融資的能力；FOXO 有虧損歷史，未來可能無法實現或維持盈利的風險；FOXO 的知識產權的可執行性，包括其專利，以及可能侵犯他人知識產權的風險；以及 FOXO 所處的高度競爭行業中經濟下滑和監管環境變化的風險。上述因素的清單並不詳盡。讀者應仔細考慮上述因素以及 FOXO 最近在 10-K 和 10-Q 表格中討論的其他風險和不確定性，特別是這些報告的 “風險因素” 部分，以及 FOXO 已提交或將提交給 SEC 的其他文件。這些文件識別並解決了可能導致實際事件和結果與前瞻性聲明中包含的內容有重大差異的其他重要風險和不確定性。前瞻性聲明僅在作出之日有效。讀者被警告不要過度依賴前瞻性聲明，FOXO 不承擔任何義務，也不打算更新或修訂這些前瞻性聲明，無論是由於新信息、未來事件還是其他原因。</p>
<p><strong>聯繫方式：</strong></p>
<p>Sebastien Sainsbury</p>
<p>ssainsbury@foxotechnologies.com</p>
<p>(561) 485-0151</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeU56RTBNQ00zTVRReE5EazNJelV3TURFeU9UQXpNUT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeU56RTBNQ00zTVRReE5EazNJelV3TURFeU9UQXpNUT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NDI0OGFjMzEtMDBiNC00YjFiLWEyMTMtODg1NTU4ZDdmMTRmLTUwMDEyOTAzMS0yMDI1LTA5LTExLWVu/tiny/FOXO-Technologies-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NDI0OGFjMzEtMDBiNC00YjFiLWEyMTMtODg1NTU4ZDdmMTRmLTUwMDEyOTAzMS0yMDI1LTA5LTExLWVu/tiny/FOXO-Technologies-Inc-.png"/></p>

FOXO

<p>FOXO Technologies Inc. 已簽署股票購買協議，以現金、60,000 股 E 系列優先股和價值 200 萬美元的普通股認股權證，總預計購買價格為 500,000 美元收購 Vector Biosource Inc.。Vector 在 2025 年第二季度的淨收入約為 225,000 美元，預計收購後將顯著增長。FOXO 計劃為 Vector 的增長計劃提供高達 120 萬美元的支持。這筆收購被視為增強 FOXO 在醫療服務領域地位的戰略舉措</p>

<p>09/11/2025 - 07:42 AM</p>
<div class="lb-trans"><p>2025 年 9 月 11 日- 上午 7:42</p>
</div><p>WEST PALM BEACH, FL, Sept. 11, 2025 (GLOBE NEWSWIRE) -- <strong>FOXO Technologies Inc.(OTC:FOXO)</strong>(the “Company”), announces that it has signed a stock purchase agreement to acquire Vector Biosource Inc. (“Vector”). Vector is an information, data and biospecimen sourcing provider serving the biotechnology, clinical research and pharmaceutical research industries. Vector generated second quarter 2025 net revenues of approximately $225,000 ($0.9 million on an annual run rate basis) and is expected to grow significantly post-acquisition.</p>
<div class="lb-trans"><p>佛羅里達州西棕櫚灘，2025 年 9 月 11 日（GLOBE NEWSWIRE）-- <strong>FOXO Technologies Inc.(OTC:FOXO)</strong>（“公司”）宣佈已簽署股票購買協議，以收購 Vector Biosource Inc.（“Vector”）。Vector 是一家為生物技術、臨牀研究和製藥研究行業提供信息、數據和生物樣本來源的供應商。Vector 在 2025 年第二季度的淨收入約為 225,000 美元（按年化計算為 90 萬美元），預計在收購後將顯著增長。</p>
</div><p>The expected purchase price consists of: (i) $500,000 in cash, (ii) 60,000 shares of the Company’s Series E Cumulative Redeemable Secured Preferred Stock (the “Series E Preferred Stock”) ($1.5 million in stated value), (iii) warrants to purchase $2 million of the Company’s common stock at a 10% premium to the common stock’s closing price one day prior to closing, and (iv) up to an additional 80,000 shares of Series E Preferred Stock (up to $2.0 million in stated value) subject to achieving certain revenue and cash collection milestones in a future 12 to 24 month period. Closing is expected to occur as soon as practical after a number of closing conditions are satisfied including, but not limited to, completion of due diligence and forms of warrant and employment agreements being finalized. In addition, FOXO has agreed to fund up to $1.2 million of Vector’s growth initiatives. Information on Vector Biosource can be found at www.vectorbiosource.com</p>
<div class="lb-trans"><p>預計購買價格包括：（i）50 萬美元現金，（ii）60,000 股公司的 E 系列累積可贖回優先股（“E 系列優先股”）（面值 150 萬美元），（iii）以比收盤價高 10% 的溢價購買 200 萬美元公司普通股的認股權證，以及（iv）最多額外 80,000 股 E 系列優先股（面值最多 200 萬美元），這取決於在未來 12 到 24 個月內實現某些收入和現金回收里程碑。預計在滿足多項成交條件後儘快完成交易，包括但不限於盡職調查的完成和認股權證及僱傭協議的最終確定。此外，FOXO 已同意為 Vector 的增長計劃提供最多 120 萬美元的資金。有關 Vector Biosource 的信息可以在 www.vectorbiosource.com 找到。</p>
</div><p>“We are pleased to have reached agreement with Vector to move forward with this strategic acquisition,” said Seamus Lagan, Chief Executive Officer of FOXO. “We are attracted to Vector’s position in this sector of healthcare services, its business fundamentals and growth profile and intend to work closely with Vector senior leadership to aggressively expand Vector through organic growth and potentially acquisitions.” Frank Dias, Jr., CEO of Vector explained, “We believe the partnership with FOXO will allow Vector to achieve its near and long-term growth plans by providing growth capital, corporate infrastructure and potential synergies with other FOXO subsidiaries.”</p>
<div class="lb-trans"><p>“我們很高興與 Vector 達成協議，推進這一戰略收購，” FOXO 首席執行官 Seamus Lagan 表示。“我們被 Vector 在醫療服務領域的地位、其商業基本面和增長前景所吸引，並打算與 Vector 的高級領導層緊密合作，通過有機增長和潛在收購積極擴展 Vector。” Vector 的首席執行官 Frank Dias, Jr.解釋道：“我們相信與 FOXO 的合作將使 Vector 能夠通過提供增長資金、企業基礎設施和與其他 FOXO 子公司的潛在協同效應，實現其近期和長期的增長計劃。”</p>
</div><p>This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations of offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (&#34;Securities Act&#34;). This announcement is being issued in accordance with Rule 135 under the Securities Act.</p>
<div class="lb-trans"><p>本新聞稿不構成出售任何證券的要約或購買任何證券的要約邀請。任何要約、購買要約的邀請或任何證券的銷售將根據《1933 年證券法》（修訂版）（“證券法”）的註冊要求進行。本公告是根據證券法第 135 條發佈的。</p>
</div><p><strong>AboutFOXO Technologies Inc.(“FOXO”)</strong></p>
<div class="lb-trans"><p><strong>關於 FOXO Technologies Inc.（“FOXO”）</strong></p>
</div><p>FOXOowns and operates three subsidiaries.</p>
<div class="lb-trans"><p>FOXO 擁有並運營三家子公司。</p>
</div><p>Rennova Community Health, Inc. owns and operates Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical Center), a critical access designated (CAH) hospital in East Tennessee.</p>
<div class="lb-trans"><p>Rennova Community Health, Inc.擁有並運營 Scott County Community Hospital, Inc.（以 Big South Fork Medical Center 為名），這是位於東田納西州的一家關鍵接入醫院（CAH）。</p>
</div><p>Myrtle Recovery Centers, Inc., a 30-bed behavioral health facility in East Tennessee. Myrtle provides inpatient services for detox and residential treatment and outpatient services for MAT and OBOT Programs.</p>
<div class="lb-trans"><p>Myrtle Recovery Centers, Inc.是一家位於東田納西州的 30 牀位行為健康設施。Myrtle 提供住院戒毒和住院治療服務，以及 MAT 和 OBOT 項目的門診服務。</p>
</div><p>FOXO Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries.</p>
<div class="lb-trans"><p>FOXO Labs, Inc.是一家生物技術公司，致力於通過開發尖端技術和產品解決方案來改善人類健康和壽命，服務於各個行業。</p>
</div><p>For more information aboutFOXO, visitwww.foxotechnologies.com.</p>
<div class="lb-trans"><p>有關 FOXO 的更多信息，請訪問 www.foxotechnologies.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the FOXO’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to the risk of changes in the competitive and highly regulated industries in which FOXO operates; variations in operating performance across competitors or changes in laws and regulations affecting FOXO’s business; the ability to implement FOXO’s business plans, forecasts, and other expectations; the ability to obtain financing; the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and the risk of downturns and a changing regulatory landscape in the highly competitive industries in which FOXO operates. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO’s most recent reports on Forms 10-K and 10-Q, particularly the “Risk Factors” sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.</p>
<div class="lb-trans"><p>本新聞稿包含前瞻性聲明。這些聲明是在 1995 年美國私人證券訴訟改革法的 “安全港” 條款下作出的。非歷史事實的聲明，包括關於 FOXO 的信念和期望的聲明，均為前瞻性聲明。前瞻性聲明涉及固有的風險和不確定性，許多因素可能導致實際結果與任何前瞻性聲明中包含的結果有重大差異。這些因素包括但不限於 FOXO 所處的競爭激烈且高度監管的行業中變化的風險；競爭對手之間的運營表現差異或影響 FOXO 業務的法律法規變化；實施 FOXO 的商業計劃、預測和其他期望的能力；獲得融資的能力；FOXO 有虧損歷史，未來可能無法實現或維持盈利的風險；FOXO 的知識產權的可執行性，包括其專利，以及可能侵犯他人知識產權的風險；以及 FOXO 所處的高度競爭行業中經濟下滑和監管環境變化的風險。上述因素的清單並不詳盡。讀者應仔細考慮上述因素以及 FOXO 最近在 10-K 和 10-Q 表格中討論的其他風險和不確定性，特別是這些報告的 “風險因素” 部分，以及 FOXO 已提交或將提交給 SEC 的其他文件。這些文件識別並解決了可能導致實際事件和結果與前瞻性聲明中包含的內容有重大差異的其他重要風險和不確定性。前瞻性聲明僅在作出之日有效。讀者被警告不要過度依賴前瞻性聲明，FOXO 不承擔任何義務，也不打算更新或修訂這些前瞻性聲明，無論是由於新信息、未來事件還是其他原因。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>聯繫方式：</strong></p>
</div><p>Sebastien Sainsbury</p>
<div class="lb-trans"><p>Sebastien Sainsbury</p>
</div><p>ssainsbury@foxotechnologies.com</p>
<div class="lb-trans"><p>ssainsbury@foxotechnologies.com</p>
</div><p>(561) 485-0151</p>
<div class="lb-trans"><p>(561) 485-0151</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeU56RTBNQ00zTVRReE5EazNJelV3TURFeU9UQXpNUT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTUyNzE0MCM3MTQxNDk3IzUwMDEyOTAzMQ=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NDI0OGFjMzEtMDBiNC00YjFiLWEyMTMtODg1NTU4ZDdmMTRmLTUwMDEyOTAzMS0yMDI1LTA5LTExLWVu/tiny/FOXO-Technologies-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NDI0OGFjMzEtMDBiNC00YjFiLWEyMTMtODg1NTU4ZDdmMTRmLTUwMDEyOTAzMS0yMDI1LTA5LTExLWVu/tiny/FOXO-Technologies-Inc-.png"/></p>

FOXO 科技公司宣佈達成收購協議，將收購 Vector Biosource 公司 | FOXO 股票新聞